Saniona AB (publ) (FRA:30S)

Market Cap	182.79M +133.5%
Revenue (ttm)	40.14M +29.8%
Net Income	26.30M +50.9%
EPS	0.20 +22.2%
Shares Out	n/a
PE Ratio	6.95
Forward PE	34.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	43
Open	1.290
Previous Close	1.351
Day's Range	1.290 - 1.290
52-Week Range	0.585 - 2.575
Beta	n/a
RSI	40.31
Earnings Date	May 26, 2026

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ...

• Industry: Pharmaceutical Preparations
• Founded: 2011
• Employees: 34
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 30S

Financial Performance

In 2025, Saniona AB's revenue was 434.40 million, an increase of 29.80% compared to the previous year's 334.67 million. Earnings were 284.67 million, an increase of 50.85%.

Financial numbers in SEK